Essential Hypertension
Conditions
Keywords
Essential hypertension, LCZ696
Brief summary
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
Interventions
DRUGLCZ696
LCZ696 200 mg tablet
DRUGOlmesartan
Olmesartan 20 mg capsule
Placebo tablet of LCZ696 200 mg once daily
Placebo capsule of olmesartan 20 mg once daily
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with mild-to-moderate hypertension, untreated or currently taking antihypertensive therapy. * Treated patients (using antihypertensive treatments within 4 weeks prior to Visit 1) must have an msSBP≥150 mmHg and \<180 mmHg at the randomization visit (Visit 201) and msSBP≥140 mmHg \<180 mmHg at the visit immediately preceding Visit 201 (Visit 102 or 103). * Untreated patients (newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to Visit 1) must have an msSBP≥150 mmHg and \<180 mmHg at both Visit 1 and Visit 201. * Patients must have an absolute difference of ≤15 mmHg in msSBP between Visit 201 and the immediately preceding visit.
Exclusion criteria
* Patients with severe hypertension (msDBP ≥110 mmHg and or msSBP ≥180 mmHg). * History of angioedema, drug-related or otherwise, as reported by the patient. * History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension. * Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg | baseline, 8 weeks | Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg | baseline, 8 weeks | Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement |
| Change From Baseline in Office Pulse Pressure (msPP) | baseline, 8 weeks | Four separate sitting BP measurements should be obtained with a full two minute interval between measurements. |
| Change From Baseline in Mean 24-hour Ambulatory Blood Pressure | baseline, 8 weeks | In this analysis, mean 24 hour ambulatory systolic blood pressure maSBP, mean 24 hour ambulatory diastolic blood pressure maDBP, daytime and nightime maSBP and maDBP will be reported. Ambulatory blood pressure monitoring over a 24 hour period will be conducted at two time points during the study. |
| Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | baseline, 8 weeks | Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement |
| Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | baseline, 8 weeks | Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement |
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg | baseline, 8 weeks | Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements |
| Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | baseline, 8 weeks | Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement |
| Number of Patients Achieving Successful Blood Pressure Control | 8 weeks | Successful blood pressure control is defined as msSBP \<140 mmHg and msDBP \<90 mmHg. |
| Change From Baseline in Ambulatory Pulse Pressure | baseline, 8 weeks | Ambulatory pulse pressure (PP) is calculated by hourly ambulatory SBP and hourly ambulatory DBP over a 24-hour period. |
| Number of Responders | baseline, 8 weeks | Responders are patients with msSBP response (\<140 mmHg or ≥20 mmHg reduction from baseline) and msDBP response (\<90 mmHg or ≥10 mmHg reduction from baseline) |
| Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | baseline, 8 weeks | Participants were monitored for adverse events, serious adverse events and deaths throughout the study. |
| Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | baseline, 8 weeks | Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement |
Countries
China, Hong Kong, Philippines, Singapore, South Korea, Taiwan, Thailand
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| LCZ696 200 mg Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily. | 479 |
| LCZ696 400 mg Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken. | 472 |
| Olmesartan 20 mg Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily. | 484 |
| Total | 1,435 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 5 | 4 | 6 |
| Overall Study | Lack of Efficacy | 2 | 0 | 1 |
| Overall Study | Lost to Follow-up | 1 | 2 | 0 |
| Overall Study | Physician Decision | 1 | 1 | 1 |
| Overall Study | Protocol deviation | 0 | 2 | 2 |
| Overall Study | Subject/guardian decision | 15 | 10 | 11 |
| Overall Study | Technical problems | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | LCZ696 200 mg | LCZ696 400 mg | Olmesartan 20 mg | Total |
|---|---|---|---|---|
| Age, Continuous | 57.5 Years STANDARD_DEVIATION 10.17 | 58.1 Years STANDARD_DEVIATION 9.71 | 57.4 Years STANDARD_DEVIATION 10.14 | 57.7 Years STANDARD_DEVIATION 10.01 |
| Gender Female | 227 Participants | 229 Participants | 223 Participants | 679 Participants |
| Gender Male | 252 Participants | 243 Participants | 261 Participants | 756 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 66 / 478 | 63 / 472 | 66 / 484 |
| serious Total, serious adverse events | 5 / 478 | 3 / 472 | 6 / 484 |
Outcome results
Primary
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg
Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements.
Time frame: baseline, 8 weeks
Population: Only participants, who had both baseline and week 8 values, were included in the analysis. The FAS included all randomized participants who received study medication and had post baseline BP assessments
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCZ696 200 mg | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg | -20.48 mmHg | Standard Error 0.61 |
| Olmesartan 20 mg | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg | -18.15 mmHg | Standard Error 0.61 |
p-value: <0.00195% CI: [-4, -0.66]ANCOVA
Secondary
Change From Baseline in Ambulatory Pulse Pressure
Ambulatory pulse pressure (PP) is calculated by hourly ambulatory SBP and hourly ambulatory DBP over a 24-hour period.
Time frame: baseline, 8 weeks
Population: Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCZ696 200 mg | Change From Baseline in Ambulatory Pulse Pressure | -5.78 mmHg | Standard Error 0.23 |
| Olmesartan 20 mg | Change From Baseline in Ambulatory Pulse Pressure | -5.98 mmHg | Standard Error 0.23 |
| Olmesartan 20 mg | Change From Baseline in Ambulatory Pulse Pressure | -4.58 mmHg | Standard Error 0.23 |
Secondary
Change From Baseline in Mean 24-hour Ambulatory Blood Pressure
In this analysis, mean 24 hour ambulatory systolic blood pressure maSBP, mean 24 hour ambulatory diastolic blood pressure maDBP, daytime and nightime maSBP and maDBP will be reported. Ambulatory blood pressure monitoring over a 24 hour period will be conducted at two time points during the study.
Time frame: baseline, 8 weeks
Population: A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LCZ696 200 mg | Change From Baseline in Mean 24-hour Ambulatory Blood Pressure | maSBP | -12.07 mmHg | Standard Error 0.49 |
| LCZ696 200 mg | Change From Baseline in Mean 24-hour Ambulatory Blood Pressure | maDBP | -6.36 mmHg | Standard Error 0.31 |
| Olmesartan 20 mg | Change From Baseline in Mean 24-hour Ambulatory Blood Pressure | maSBP | -12.76 mmHg | Standard Error 0.49 |
| Olmesartan 20 mg | Change From Baseline in Mean 24-hour Ambulatory Blood Pressure | maDBP | -6.82 mmHg | Standard Error 0.31 |
| Olmesartan 20 mg | Change From Baseline in Mean 24-hour Ambulatory Blood Pressure | maSBP | -10.26 mmHg | Standard Error 0.49 |
| Olmesartan 20 mg | Change From Baseline in Mean 24-hour Ambulatory Blood Pressure | maDBP | -5.61 mmHg | Standard Error 0.31 |
Secondary
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg
Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement
Time frame: baseline, 8 weeks
Population: Participants from the full analysis set (FAS), who had both baseline and week 8 values, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| LCZ696 200 mg | Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg | -8.10 mmHg | Standard Error 0.37 |
| Olmesartan 20 mg | Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg | -8.80 mmHg | Standard Error 0.38 |
| Olmesartan 20 mg | Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg | -6.86 mmHg | Standard Error 0.37 |
Secondary
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg
Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements
Time frame: baseline, 8 weeks
Population: Only participants, who had both baseline and week 8 values, were included in the analysis. The FAS included all randomized participants who received study medication and had post baseline BP assessments
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCZ696 200 mg | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg | -21.67 mmHg | Standard Error 0.62 |
| Olmesartan 20 mg | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg | -18.15 mmHg | Standard Error 0.61 |
Secondary
Change From Baseline in Office Pulse Pressure (msPP)
Four separate sitting BP measurements should be obtained with a full two minute interval between measurements.
Time frame: baseline, 8 weeks
Population: Participants from the full analysis set (FAS), who had both baseline and endpoint were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCZ696 200 mg | Change From Baseline in Office Pulse Pressure (msPP) | -12.35 mmHg | Standard Error 0.42 |
| Olmesartan 20 mg | Change From Baseline in Office Pulse Pressure (msPP) | -12.93 mmHg | Standard Error 0.43 |
| Olmesartan 20 mg | Change From Baseline in Office Pulse Pressure (msPP) | -11.25 mmHg | Standard Error 0.42 |
Secondary
Number of Patients Achieving Successful Blood Pressure Control
Successful blood pressure control is defined as msSBP \<140 mmHg and msDBP \<90 mmHg.
Time frame: 8 weeks
Population: Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| LCZ696 200 mg | Number of Patients Achieving Successful Blood Pressure Control | 256 Number of participants |
| Olmesartan 20 mg | Number of Patients Achieving Successful Blood Pressure Control | 270 Number of participants |
| Olmesartan 20 mg | Number of Patients Achieving Successful Blood Pressure Control | 235 Number of participants |
Secondary
Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability
Participants were monitored for adverse events, serious adverse events and deaths throughout the study.
Time frame: baseline, 8 weeks
Population: Safety Set (SAF): All patients who received at least one dose of double-blind trial medication. Patients were analyzed according to the treatment they received.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| LCZ696 200 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Deaths | 0 Participants |
| LCZ696 200 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Serious adverse events | 5 Participants |
| LCZ696 200 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Adverse events (non-serious and serious | 143 Participants |
| Olmesartan 20 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Deaths | 0 Participants |
| Olmesartan 20 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Adverse events (non-serious and serious | 132 Participants |
| Olmesartan 20 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Serious adverse events | 3 Participants |
| Olmesartan 20 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Serious adverse events | 6 Participants |
| Olmesartan 20 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Adverse events (non-serious and serious | 134 Participants |
| Olmesartan 20 mg | Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability | Deaths | 0 Participants |
Secondary
Number of Responders
Responders are patients with msSBP response (\<140 mmHg or ≥20 mmHg reduction from baseline) and msDBP response (\<90 mmHg or ≥10 mmHg reduction from baseline)
Time frame: baseline, 8 weeks
Population: Participants from the full analysis set (FAS), who had both baseline and endpoint, were included in the analysis. The FAS included all participants who received study medication and had post baseline BP assessments
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| LCZ696 200 mg | Number of Responders | 312 Participants |
| Olmesartan 20 mg | Number of Responders | 314 Participants |
| Olmesartan 20 mg | Number of Responders | 290 Participants |
Secondary
Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement
Time frame: baseline, 8 weeks
Population: A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 7 | -7.15 mmHg | Standard Deviation 13.876 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 2 | -8.47 mmHg | Standard Deviation 12.343 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 3 | -9.24 mmHg | Standard Deviation 13.445 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 4 | -6.86 mmHg | Standard Deviation 13.397 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 5 | -5.27 mmHg | Standard Deviation 14.782 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 6 | -7.83 mmHg | Standard Deviation 12.628 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 1 | -7.93 mmHg | Standard Deviation 10.377 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 8 | -8.00 mmHg | Standard Deviation 11.858 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 9 | -8.88 mmHg | Standard Deviation 8.732 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 10 | -6.89 mmHg | Standard Deviation 10.063 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 11 | -5.22 mmHg | Standard Deviation 12.401 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 12 | -402 mmHg | Standard Deviation 13.637 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 13 | -6.84 mmHg | Standard Deviation 12.616 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 14 | -4.34 mmHg | Standard Deviation 12.057 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 15 | -4.53 mmHg | Standard Deviation 13.244 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 16 | -3.91 mmHg | Standard Deviation 11.469 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 17 | -6.68 mmHg | Standard Deviation 11.774 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 18 | -5.87 mmHg | Standard Deviation 12.152 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 19 | -5.32 mmHg | Standard Deviation 9.2 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 20 | -5.17 mmHg | Standard Deviation 16.028 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 21 | -6.97 mmHg | Standard Deviation 12.581 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 22 | -7.57 mmHg | Standard Deviation 11.891 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 23 | -6.12 mmHg | Standard Deviation 13.266 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 24 | -5.23 mmHg | Standard Deviation 10.793 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 22 | -11.37 mmHg | Standard Deviation 10.507 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 1 | -7.38 mmHg | Standard Deviation 8.786 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 13 | -6.33 mmHg | Standard Deviation 10.802 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 17 | -7.21 mmHg | Standard Deviation 10.46 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 2 | -10.19 mmHg | Standard Deviation 10.836 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 11 | -8.69 mmHg | Standard Deviation 12.989 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 21 | -9.44 mmHg | Standard Deviation 9.303 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 3 | -9.90 mmHg | Standard Deviation 11.353 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 14 | -6.73 mmHg | Standard Deviation 11.751 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 23 | -9.95 mmHg | Standard Deviation 10.374 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 4 | -8.65 mmHg | Standard Deviation 11.74 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 10 | -8.14 mmHg | Standard Deviation 11.244 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 18 | -6.94 mmHg | Standard Deviation 10.904 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 5 | -10.79 mmHg | Standard Deviation 12.123 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 15 | -5.51 mmHg | Standard Deviation 10.473 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 12 | -7.39 mmHg | Standard Deviation 13.722 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 6 | -11.47 mmHg | Standard Deviation 13.154 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 9 | -9.56 mmHg | Standard Deviation 12.309 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 24 | -8.62 mmHg | Standard Deviation 10.066 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 7 | -9.13 mmHg | Standard Deviation 12.99 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 16 | -7.20 mmHg | Standard Deviation 10.179 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 19 | -7.61 mmHg | Standard Deviation 11.841 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 8 | -8.90 mmHg | Standard Deviation 11.22 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 20 | -10.45 mmHg | Standard Deviation 10.969 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 8 | -7.44 mmHg | Standard Deviation 13.863 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 9 | -6.83 mmHg | Standard Deviation 13.29 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 10 | -7.07 mmHg | Standard Deviation 13.808 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 11 | -5.41 mmHg | Standard Deviation 12.983 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 20 | -3.06 mmHg | Standard Deviation 10.965 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 12 | -5.64 mmHg | Standard Deviation 12.158 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 23 | -9.89 mmHg | Standard Deviation 15.553 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 13 | -6.69 mmHg | Standard Deviation 14.822 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 14 | -3.97 mmHg | Standard Deviation 14.844 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 21 | -6.33 mmHg | Standard Deviation 12.257 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 15 | -3.85 mmHg | Standard Deviation 11.421 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 24 | -7.19 mmHg | Standard Deviation 10.504 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 16 | -2.60 mmHg | Standard Deviation 11.997 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 1 | -5.99 mmHg | Standard Deviation 11.811 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 2 | -10.49 mmHg | Standard Deviation 12.803 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 17 | -4.43 mmHg | Standard Deviation 11.789 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 3 | -9.28 mmHg | Standard Deviation 11.828 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 22 | -6.61 mmHg | Standard Deviation 12.324 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 4 | -9.80 mmHg | Standard Deviation 12.802 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 5 | -8.54 mmHg | Standard Deviation 15.816 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 18 | -6.36 mmHg | Standard Deviation 11.225 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 6 | -5.55 mmHg | Standard Deviation 14.87 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 7 | -6.23 mmHg | Standard Deviation 14.911 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers. | Hour 19 | -3.94 mmHg | Standard Deviation 11.7 |
Secondary
Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement
Time frame: baseline, 8 weeks
Population: A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 7 | -4.85 mmHg | Standard Deviation 12.321 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 2 | -5.41 mmHg | Standard Deviation 10.593 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 3 | -3.95 mmHg | Standard Deviation 11.359 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 4 | -3.68 mmHg | Standard Deviation 13.107 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 5 | -3.53 mmHg | Standard Deviation 13.159 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 6 | -4.10 mmHg | Standard Deviation 12.18 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 1 | -5.93 mmHg | Standard Deviation 9.153 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 8 | -6.07 mmHg | Standard Deviation 11.764 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 9 | -4.34 mmHg | Standard Deviation 11.489 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 10 | -5.53 mmHg | Standard Deviation 10.639 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 11 | -4.53 mmHg | Standard Deviation 10.52 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 12 | -5.43 mmHg | Standard Deviation 10.795 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 13 | -5.57 mmHg | Standard Deviation 12.269 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 14 | -6.18 mmHg | Standard Deviation 12.291 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 15 | -7.29 mmHg | Standard Deviation 12.351 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 16 | -7.68 mmHg | Standard Deviation 12.231 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 17 | -7.28 mmHg | Standard Deviation 12.097 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 18 | -8.38 mmHg | Standard Deviation 11.421 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 19 | -9.02 mmHg | Standard Deviation 11.661 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 20 | -8.92 mmHg | Standard Deviation 11.687 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 21 | -8.05 mmHg | Standard Deviation 10.48 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 22 | -7.16 mmHg | Standard Deviation 10.06 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 23 | -6.34 mmHg | Standard Deviation 10.752 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 24 | -5.86 mmHg | Standard Deviation 9.93 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 22 | -6.55 mmHg | Standard Deviation 8.317 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 1 | -6.57 mmHg | Standard Deviation 10.35 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 13 | -5.01 mmHg | Standard Deviation 13.67 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 17 | -7.84 mmHg | Standard Deviation 11.479 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 2 | -551 mmHg | Standard Deviation 11.655 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 11 | -4.10 mmHg | Standard Deviation 11.889 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 21 | -7.24 mmHg | Standard Deviation 12.056 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 3 | -4.20 mmHg | Standard Deviation 12.472 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 14 | -5.91 mmHg | Standard Deviation 12.409 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 23 | -5.19 mmHg | Standard Deviation 11.593 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 4 | -3.53 mmHg | Standard Deviation 11.966 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 10 | -4.48 mmHg | Standard Deviation 10.549 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 18 | -8.81 mmHg | Standard Deviation 10.385 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 5 | -3.14 mmHg | Standard Deviation 12.208 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 15 | -5.95 mmHg | Standard Deviation 11.443 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 12 | -4.42 mmHg | Standard Deviation 11.973 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 6 | -3.55 mmHg | Standard Deviation 10.888 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 9 | -4.78 mmHg | Standard Deviation 10.645 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 24 | -6.05 mmHg | Standard Deviation 9.926 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 7 | -3.31 mmHg | Standard Deviation 12.281 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 16 | -7.26 mmHg | Standard Deviation 10.726 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 19 | -8.77 mmHg | Standard Deviation 10.56 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 8 | -2.22 mmHg | Standard Deviation 11.449 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 20 | -7.12 mmHg | Standard Deviation 10.02 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 8 | -3.44 mmHg | Standard Deviation 12.022 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 9 | -4.54 mmHg | Standard Deviation 12.454 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 10 | -3.57 mmHg | Standard Deviation 12.906 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 11 | -5.51 mmHg | Standard Deviation 13.254 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 20 | -5.80 mmHg | Standard Deviation 11.234 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 12 | -4.50 mmHg | Standard Deviation 11.743 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 23 | -6.26 mmHg | Standard Deviation 9.552 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 13 | -6.04 mmHg | Standard Deviation 12.832 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 14 | -5.26 mmHg | Standard Deviation 12.249 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 21 | -6.49 mmHg | Standard Deviation 12.078 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 15 | -7.52 mmHg | Standard Deviation 12.395 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 24 | -4.96 mmHg | Standard Deviation 9.716 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 16 | -6.96 mmHg | Standard Deviation 11.524 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 1 | -4.57 mmHg | Standard Deviation 10.648 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 2 | -5.49 mmHg | Standard Deviation 11.892 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 17 | -6.14 mmHg | Standard Deviation 12.302 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 3 | -4.44 mmHg | Standard Deviation 12.069 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 22 | -5.65 mmHg | Standard Deviation 11.711 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 4 | -4.70 mmHg | Standard Deviation 12.29 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 5 | -3.81 mmHg | Standard Deviation 13.309 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 18 | -5.28 mmHg | Standard Deviation 12.401 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 6 | -2.94 mmHg | Standard Deviation 13.162 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 7 | -2.71 mmHg | Standard Deviation 13 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers. | Hour 19 | -5.20 mmHg | Standard Deviation 11.211 |
Secondary
Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement
Time frame: baseline, 8 weeks
Population: A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 17 | -10.20 mmHg | Standard Deviation 15.78 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 8 | -13.84 mmHg | Standard Deviation 17.365 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 24 | -8.43 mmHg | Standard Deviation 15.33 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 18 | -9.84 mmHg | Standard Deviation 15.789 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 6 | -13.66 mmHg | Standard Deviation 16.785 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 23 | -9.23 mmHg | Standard Deviation 20.068 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 19 | -8.94 mmHg | Standard Deviation 12.283 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 12 | -8.99 mmHg | Standard Deviation 17.913 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 22 | -12.62 mmHg | Standard Deviation 17.527 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 20 | -8.03 mmHg | Standard Deviation 19.411 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 10 | -13.81 mmHg | Standard Deviation 17.67 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 21 | -9.47 mmHg | Standard Deviation 16.984 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 5 | -11.19 mmHg | Standard Deviation 19.376 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 13 | -12.46 mmHg | Standard Deviation 18.694 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 4 | -13.09 mmHg | Standard Deviation 19.46 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 14 | -9.64 mmHg | Standard Deviation 17.001 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 9 | -16.33 mmHg | Standard Deviation 16.437 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 3 | -14.99 mmHg | Standard Deviation 19.378 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 15 | -7.73 mmHg | Standard Deviation 17.362 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 7 | -11.74 mmHg | Standard Deviation 21.552 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 2 | -17.24 mmHg | Standard Deviation 20.423 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 16 | -4.92 mmHg | Standard Deviation 14.788 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 11 | -12.98 mmHg | Standard Deviation 16.856 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 1 | -13.22 mmHg | Standard Deviation 16.506 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 13 | -13.28 mmHg | Standard Deviation 17.014 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 9 | -15.64 mmHg | Standard Deviation 18.915 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 10 | 15.13 mmHg | Standard Deviation 18.014 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 11 | -15.93 mmHg | Standard Deviation 19.022 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 12 | -15.54 mmHg | Standard Deviation 20.397 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 14 | -12.33 mmHg | Standard Deviation 16.449 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 15 | -10.12 mmHg | Standard Deviation 14.433 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 16 | -12.82 mmHg | Standard Deviation 13.386 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 17 | -12.43 mmHg | Standard Deviation 14.397 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 18 | -11.70 mmHg | Standard Deviation 13.799 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 19 | -12.20 mmHg | Standard Deviation 15.012 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 20 | -15.04 mmHg | Standard Deviation 14.647 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 21 | -14.33 mmHg | Standard Deviation 13.585 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 22 | -17.20 mmHg | Standard Deviation 14.304 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 23 | -16.63 mmHg | Standard Deviation 15.752 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 24 | -15.76 mmHg | Standard Deviation 17.392 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 1 | -15.02 mmHg | Standard Deviation 14.578 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 2 | -18.11 mmHg | Standard Deviation 15.343 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 3 | -16.83 mmHg | Standard Deviation 16.312 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 4 | -16.37 mmHg | Standard Deviation 18.71 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 5 | -18.88 mmHg | Standard Deviation 16.636 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 6 | -19.19 mmHg | Standard Deviation 17.771 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 7 | -18.07 mmHg | Standard Deviation 19.748 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 8 | -16.12 mmHg | Standard Deviation 16.696 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 16 | -4.40 mmHg | Standard Deviation 15.974 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 9 | -13.33 mmHg | Standard Deviation 18.36 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 1 | -9.07 mmHg | Standard Deviation 17.597 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 15 | -7.81 mmHg | Standard Deviation 15.383 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 6 | -11.54 mmHg | Standard Deviation 21.885 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 2 | -13.95 mmHg | Standard Deviation 19.247 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 14 | -6.66 mmHg | Standard Deviation 17.906 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 10 | -10.89 mmHg | Standard Deviation 19.814 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 3 | -14.51 mmHg | Standard Deviation 18.436 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 13 | -11.49 mmHg | Standard Deviation 18.587 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 8 | -12.99 mmHg | Standard Deviation 20.555 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 4 | -14.63 mmHg | Standard Deviation 18.824 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 20 | -4.83 mmHg | Standard Deviation 15.953 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 12 | -10.51 mmHg | Standard Deviation 19.516 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 21 | -9.97 mmHg | Standard Deviation 16.552 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 19 | -5.76 mmHg | Standard Deviation 16.029 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 7 | -11.74 mmHg | Standard Deviation 24.674 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 22 | -9.95 mmHg | Standard Deviation 18.49 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 18 | -8.90 mmHg | Standard Deviation 14.907 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 5 | -14.64 mmHg | Standard Deviation 21.177 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 23 | -14.09 mmHg | Standard Deviation 25.454 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 17 | -7.19 mmHg | Standard Deviation 14.937 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 11 | -7.66 mmHg | Standard Deviation 18.816 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers. | Hour 24 | -12.71 mmHg | Standard Deviation 15.199 |
Secondary
Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement
Time frame: baseline, 8 weeks
Population: A subset of participants, who participated in ambulatory blood pressure monitoring, was analyzed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 21 | -14.10 mmHg | Standard Deviation 15.413 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 17 | -14.00 mmHg | Standard Deviation 16.145 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 18 | -15.93 mmHg | Standard Deviation 16.18 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 19 | -16.45 mmHg | Standard Deviation 16.8 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 20 | -15.29 mmHg | Standard Deviation 16.22 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 7 | -9.07 mmHg | Standard Deviation 17.599 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 6 | -8.71 mmHg | Standard Deviation 16.7 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 22 | -13.97 mmHg | Standard Deviation 15.504 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 3 | -10.03 mmHg | Standard Deviation 15.654 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 23 | -11.91 mmHg | Standard Deviation 15.622 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 8 | -11.07 mmHg | Standard Deviation 16.115 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 24 | -13.07 mmHg | Standard Deviation 15.572 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 9 | -10.31 mmHg | Standard Deviation 16.749 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 1 | -11.29 mmHg | Standard Deviation 15.196 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 10 | -11.48 mmHg | Standard Deviation 16.782 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 4 | -8.79 mmHg | Standard Deviation 17.07 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 11 | -10.01 mmHg | Standard Deviation 15.182 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 12 | -12.37 mmHg | Standard Deviation 15.745 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 2 | -10.51 mmHg | Standard Deviation 16.652 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 13 | -13.49 mmHg | Standard Deviation 17.706 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 5 | -7.84 mmHg | Standard Deviation 17.29 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 14 | -13.20 mmHg | Standard Deviation 16.747 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 15 | -14.01 mmHg | Standard Deviation 17.729 |
| LCZ696 200 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 16 | -15.15 mmHg | Standard Deviation 15.683 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 3 | -9.82 mmHg | Standard Deviation 18.755 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 5 | -8.15 mmHg | Standard Deviation 16.984 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 17 | -14.71 mmHg | Standard Deviation 16.069 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 6 | -7.77 mmHg | Standard Deviation 17.722 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 9 | -10.65 mmHg | Standard Deviation 15.636 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 18 | -15.37 mmHg | Standard Deviation 14.999 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 16 | -14.04 mmHg | Standard Deviation 15.09 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 19 | -16.04 mmHg | Standard Deviation 15.968 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 1 | -10.38 mmHg | Standard Deviation 15.257 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 13 | 10.64 mmHg | Standard Deviation 19.736 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 20 | -14.20 mmHg | Standard Deviation 16.727 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 10 | -10.68 mmHg | Standard Deviation 17.256 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 15 | -11.95 mmHg | Standard Deviation 16.789 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 21 | -15.26 mmHg | Standard Deviation 17.307 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 7 | -8.27 mmHg | Standard Deviation 19.157 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 2 | -11.07 mmHg | Standard Deviation 17.183 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 22 | -12.79 mmHg | Standard Deviation 14.252 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 11 | -8.96 mmHg | Standard Deviation 19.195 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 4 | -5.77 mmHg | Standard Deviation 17.588 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 23 | -9.55 mmHg | Standard Deviation 17.616 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 14 | -13.34 mmHg | Standard Deviation 18.467 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 12 | -11.55 mmHg | Standard Deviation 18.456 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 24 | -11.81 mmHg | Standard Deviation 16.006 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 8 | -8.30 mmHg | Standard Deviation 16.824 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 24 | -7.57 mmHg | Standard Deviation 15.992 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 1 | -9.37 mmHg | Standard Deviation 16.751 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 2 | -10.26 mmHg | Standard Deviation 16.202 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 3 | -9.10 mmHg | Standard Deviation 17.448 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 4 | -7.55 mmHg | Standard Deviation 19.225 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 5 | -6.40 mmHg | Standard Deviation 19.817 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 6 | -6.51 mmHg | Standard Deviation 19.439 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 7 | -6.93 mmHg | Standard Deviation 17.751 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 8 | -6.36 mmHg | Standard Deviation 18.156 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 9 | -8.70 mmHg | Standard Deviation 18.304 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 10 | -7.55 mmHg | Standard Deviation 18.87 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 11 | -9.49 mmHg | Standard Deviation 17.537 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 12 | -8.25 mmHg | Standard Deviation 17.806 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 13 | -9.82 mmHg | Standard Deviation 18.908 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 14 | -10.24 mmHg | Standard Deviation 17.972 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 15 | -12.62 mmHg | Standard Deviation 16.855 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 16 | -12.52 mmHg | Standard Deviation 15.137 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 17 | -11.71 mmHg | Standard Deviation 17.849 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 19 | -10.37 mmHg | Standard Deviation 15.684 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 20 | -10.90 mmHg | Standard Deviation 15.129 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 21 | -10.52 mmHg | Standard Deviation 16.818 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 22 | -10.67 mmHg | Standard Deviation 17.877 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 23 | -10.77 mmHg | Standard Deviation 15.363 |
| Olmesartan 20 mg | Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers. | Hour 18 | -9.97 mmHg | Standard Deviation 17.116 |